Benzinga's Top #PreMarket Gainers

shares rose 62.50 percent to $7.54 in pre-market trading following the report of positive results from Phase 3 trial of Plecanatide.

shares climbed 22.69 percent to $74.50 in pre-market trading after

announced its plans to buy Kythera Biopharma for $2.1 billion in cash & stock.

gained 12.10 percent to $74.00 in pre-market trading after the company reported a receipt of preliminary non-binding offer to purchase the company at $77 per ADS.

shares rose 5.18 percent to $78.65 in pre-market trading after falling 3.46 percent on Tuesday.

shares climbed 5.05 percent to $49.90 in pre-market trading after the company reported better-than-expected results for its fiscal fourth quarter.